Researchers have clarified the contribution of IL-12 and IL-23 in immune regulation.
The development pipeline for psoriasis in summary.
Proteomic technologies have ushered in a new era in biomarker discovery that may revolutionize the diagnosis and treatment of rheumatic diseases.
Three recent cases of fatal reactions to low-dose oral methotrexate due to interactions and dosing errors highlight the need to improve safety.
Research highlights success in treat-to-target and early treatment of psoriatic arthritis.
Organized collaborations and advances in technology have contributed to improved treatment of rheumatic diseases that affect children.
The past 10 years have been marked “an explosion” of new therapies for use across the spectrum of rheumatic diseases, some with outstanding success, others, not so.
Etanercept is a viable long-term treatment strategy for patients with psoriatic arthritis, and is both safe and effective when used in daily clinical practice, according to a new prospective long-term study.
The common practice of dose-escalating TNF inhibitors to retain clinical response may not be the most cost-effective approach in rheumatoid arthritis, study shows.
A new study finds promise in the combination of toclizumab and methotrexate as a treatment for early rheumatoid arthritis.